Earnings report for ProQR Therapeutics N.V. (NASDAQ:PRQR) is expected on May, 8., as reported by Faxor. Analysts predict 12.20 % diference or $-0.36 from the $-0.41 EPS from 2018. Last quarter $-0.38 EPS was reported. Analysts predicts -5.26 % EPS growth this quarter. The stock decreased 7.10% or $1 during the last trading session, reaching $13.09.Currently ProQR Therapeutics N.V. is uptrending after 366.35% change in last April 15, 2018. PRQR has also 172,628 shares volume. PRQR outperformed by 361.98% the S&P 500.

ProQR Therapeutics N.V. (NASDAQ:PRQR) Ratings Coverage

In total 2 analysts cover ProQR Therapeutics (NASDAQ:PRQR). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 3 are the (NASDAQ:PRQR)’s analyst reports since November 14, 2018 according to StockzIntelligence Inc. On Thursday, February 28 the firm earned “Buy” rating by H.C. Wainwright.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA therapeutics for the treatment of genetic disorders.The company has $508.85 million market cap. The Company’s lead product candidate includes QR-010, a RNA oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa.Currently it has negative earnings. The firm has a research collaboration agreement with Galapagos N.V. to discover Axiomer Editing Oligonucleotides against fibrosis targets.

For more ProQR Therapeutics N.V. (NASDAQ:PRQR) news announced recently go to: Globenewswire.com, Streetinsider.com, Nasdaq.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “ProQR to Present at Cowen Health Care Conference – GlobeNewswire” announced on March 05, 2019, “ProQR (PRQR) spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics – StreetInsider.com” on March 26, 2019, “Health Care Sector Update for 01/02/2019: OBLN,NTEC,PRQR,GMED – Nasdaq” with a publish date: January 02, 2019, “ProQR Therapeutics Added to NASDAQ Biotechnology Index – GlobeNewswire” and the last “ProQR Therapeutics: What’s Bigger, Its Pipeline Or Its 2019 Outlook? – Seeking Alpha” with publication date: March 05, 2019.